Back to News
Jun 4, 2026 4:00 PM

Wall Street May Be Mispricing Medtronic, Analyst Says

On Wednesday, Medtronic plc (NYSE:MDT) reported fourth-quarter revenue that exceeded Wall Street expectations, supported by strong growth in its Cardiovascular and Diabetes businesses.

Earnings Beat Expectations

Adjusted earnings came in at $1.55 per share, slightly above analysts’ estimates of $1.54 per share.

Revenue increased 9.9% year over year to $9.81 billion, topping the consensus estimate of $9.64 billion. Organic revenue growth was 6.6%.

Cardiovascular revenue rose 13.8% year over year to $3.80 billion, or 10.1% organically, driven by high-teens growth in Cardiac Rhythm & Heart Failure and modest gains in Structural Heart & Aortic and Coronary & Peripheral Vascular.

Read Also:

First-Ever Autism ETF Hits Market As Health Care Innovation Theme Gains Momentum

BTIG Upgrades Medtronic

BTIG upgraded Medtronic from Neutral to Buy, with a price forecast ...